Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients

Ding, Tao; Wang, Xin; Fu, Adan; Xu, Liwen; Lin, Jing

doi:10.1097/md.0000000000017314

Cited by 25 publications

(23 citation statements)

References 24 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the United States, head and neck cancer (HNC) accounts for approximately 3.6% of cancers, with an estimated 65 000 Americans developing HNC and 14 750 dying from the disease annually 1 . In recent years, there has been mounting evidence to support the claim that depression and depressive symptoms play a role in cancer prognosis 2–9 . For instance, studies have found that depression is associated with worse all‐cause mortality for both patients with breast cancer and patients with metastatic prostate cancer 10,11 …”

Section: Introductionmentioning

confidence: 99%

“…1 In recent years, there has been mounting evidence to support the claim that depression and depressive symptoms play a role in cancer prognosis. [2][3][4][5][6][7][8][9] For instance, studies have found that depression is associated with worse all-cause mortality for both patients with breast cancer and patients with metastatic prostate cancer. 10,11 It has also been noted that patients with HNC experience rates of depression higher than those of the overall population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic impact of depression or depressive symptoms on patients with head and neck cancer: A systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

Background This systematic review and meta‐analysis sought to assess the extent to which pretreatment depression or depressive symptoms are related to prognosis in patients with head and neck cancer (HNC). Methods Medline, EMbase, Scopus, and The Cochrane Library databases were searched. A meta‐analysis was done to generate a forest plot and pooled hazard ratio (HR) with 95% CI for overall survival (OS). RevMan 5.3 and Meta Essentials were used for statistical analysis. Results Based on seven studies involving 1743 patients, the results showed that HNC patients with pretreatment depression or depressive symptoms had worse OS than patients without depression or depressive symptoms, with an HR of 1.33, 95% CI 1.16–1.52, p = <0.0001. There is heterogeneity in the pooled summary effect (I2 = 80%, p < 0.0001). Conclusions Pretreatment depression or depressive symptoms may indicate worse OS in patients with HNC. The pooled analysis demonstrated a statistically significant effect. These results were limited by mild heterogeneity.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The prognostic impact of depression or depressive symptoms on patients with head and neck cancer: A systematic review and meta‐analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Due to the sudden onset and need to treat rapidly, patients with AML also reported feeling overwhelmed and had trouble processing the large quantity of information regarding their diagnosis and potential treatment options, which may have contributed to increases in psychological distress and feelings of helplessness [34]. In a recent publication, anxiety and depression are frequent in adult patients with AML and both predict unfavorable survival [35].…”

Section: Qol and Psychological Considerations In Amlmentioning

confidence: 99%

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

Meillón-Garcı́a

Demichelis‐Gómez

2020

Curr Oncol Rep

View full text Add to dashboard Cite

Purpose of Review Acute myeloid leukemia (AML) is a costly disease, and its impact is greater in developing countries (DC). We will review the current concept of what are DC, compare the differences in the epidemiology and economic burden of this disease between developed and DC, and finally, analyze the barriers and possible solutions that DC should implement to achieve better results. Recent Findings DC is a frequently misunderstood name. The way we use to measure human development is changing, and multidimension metrics better define what are DC. With this in mind, we show the differences in the AML epidemiology and the impact of economic burden in DC. We analyze the barriers to access therapy from a clinician point of view, to show that most DC shared similar challenges but with a diverse healthcare structure. Finally, we provide several possible solutions for a more integrated and timely treatment that allows better results not only in terms of survival but with a better quality of life. Summary The economic burden of AML treatment in DC is high, and the results are poor. It is crucial to face this challenge and propose new treatment approaches to achieve better results.

show abstract

“…This group of patients has more than twice as high probability of death than those without cognitive deficit 37 . Similarly, fatigue, depressions, and anxiety as negative risk factors with a high incidence in this patient group are completely omitted 50,51 . Considering all the facts, it is important to find a more complex approach that includes apart from the comorbidities also cognitive function, physical function including risk of falls, nutrition, and a psychosocial state as a bare minimum.…”

Section: Geriatric Assessment and Why A Complex Approach Is Neededmentioning

confidence: 99%

How to select older patients with acute myeloid leukemia fit for intensive treatment?

Šustková

Semerád

Weinbergerová

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

Outcomes of the treatment of older patients with acute myeloid leukemia (AML) are unsatisfactory due to a higher incidence of negative patient‐ and disease‐related risk factors connected with aging. Prediction of poor tolerance to aggressive treatment and low response to standard intensive chemotherapy are the main root causes why the treatment decision is challenging. For a long time, negative prognostic factors for treatment outcomes, overall survival, and early death such as the age itself, low‐performance status, high‐comorbidity burden, adverse cytogenetics, and secondary AML have been known, and they are routinely taken into account during therapeutic balance. In consideration of the risk factors and specific laboratory results, prognostic models have been created. Despite the abovementioned facts, the survival of older patients with AML remains very poor, that holds true even for the intensive therapy. For that reason, there is an increased effort to find a better approach how to select patients who would benefit from intensive treatment without decreasing their quality of life through severe complications with risk of high treatment‐related mortality. Based on the results of clinical studies, the geriatric assessment could be the missing step which would help select older patients who are really fit for intensive treatment and who will benefit from it the most. This review focuses on the risk factors that should be taken under advisement when the decision about the treatment is made. With reference to the published information, we propose an algorithm how to identify fit, vulnerable, and frail patients.

show abstract

Anxiety and depression predict unfavorable survival in acute myeloid leukemia patients

Cited by 25 publications

References 24 publications

The prognostic impact of depression or depressive symptoms on patients with head and neck cancer: A systematic review and meta‐analysis

The prognostic impact of depression or depressive symptoms on patients with head and neck cancer: A systematic review and meta‐analysis

Access to Therapy for Acute Myeloid Leukemia in the Developing World: Barriers and Solutions

How to select older patients with acute myeloid leukemia fit for intensive treatment?

Contact Info

Product

Resources

About